Mirum Pharmaceuticals, Inc. Increase (Decrease) in Inventories
Mirum Pharmaceuticals, Inc. (MIRM) reported Increase (Decrease) in Inventories of $1.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$395.00K, a 116.92% decline year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was $1.92M, a 28.14% decline year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $2.28M, a 966.36% increase year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was $1.16M, a 28.35% increase year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2025 was $8.45M, a 166.84% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2024 was $3.17M, a 225.05% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2023 was $974.00K, a 71.75% decline from fiscal 2022.
- Mirum Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2022 was $3.45M, a 596.57% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 3 month as first filed | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 6 month as first filed | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month | Increase (Decrease) in Inventories 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$395.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.52M 10-Q · filed 2026-08-05 | $3.81M derived: sum of 3 quarters · filed 2026-08-05 | $4.97M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $1.92M 10-Q · filed 2026-05-06 | $4.20M derived: sum of 2 quarters · filed 2026-05-06 | $5.36M derived: sum of 3 quarters · filed 2026-05-06 | $7.70M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.44M derived: sum of 2 quarters · filed 2026-02-25 | $5.78M derived: sum of 3 quarters · filed 2026-08-05 | $8.45M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.49M derived: sum of 2 quarters · filed 2026-08-05 | $6.17M 10-Q · filed 2025-11-04 | $6.38M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.01M 10-Q · filed 2026-08-05 | $5.22M derived: sum of 3 quarters · filed 2026-08-05 | $6.12M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $2.67M 10-Q · filed 2026-05-06 | $2.89M derived: sum of 2 quarters · filed 2026-05-06 | $3.79M derived: sum of 3 quarters · filed 2026-05-06 | $4.87M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.12M derived: sum of 2 quarters · filed 2026-02-25 | $2.20M derived: sum of 3 quarters · filed 2026-02-25 | $3.17M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $903.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.99M derived: sum of 2 quarters · filed 2025-11-04 | $2.95M 10-Q · filed 2025-11-04 | $1.72M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.05M 10-Q · filed 2025-08-06 | $6.62M 10-Q · filed 2024-08-07 | $817.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.26M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $964.00K 10-Q · filed 2025-05-07 | $3.17M 10-Q · filed 2024-05-08 | -$268.00K derived: sum of 2 quarters · filed 2026-02-25 | $171.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.16M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$793.00K derived: sum of 2 quarters · filed 2026-02-25 | $196.00K derived: sum of 3 quarters · filed 2026-02-25 | $974.00K 10-K · filed 2026-02-25 | $4.39M 10-K · filed 2024-03-15 | ||
| 2023-09-30 | $439.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.43M derived: sum of 2 quarters · filed 2024-11-12 | $2.21M 10-Q · filed 2024-11-12 | $1.61M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2023-06-30 | $989.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.77M 10-Q · filed 2024-08-07 | $1.17M derived: sum of 3 quarters · filed 2025-02-26 | $3.97M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2023-03-31 | $778.00K 10-Q · filed 2024-05-08 | $180.00K derived: sum of 2 quarters · filed 2025-02-26 | $2.98M derived: sum of 3 quarters · filed 2025-02-26 | $4.16M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2022-12-31 | -$598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.20M derived: sum of 2 quarters · filed 2025-02-26 | $3.38M derived: sum of 3 quarters · filed 2025-02-26 | $3.45M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.98M derived: sum of 2 quarters · filed 2023-11-02 | $4.05M 10-Q · filed 2023-11-02 | $4.54M derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2022-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.25M 10-Q · filed 2023-08-07 | $1.74M derived: sum of 3 quarters · filed 2024-03-15 | $1.74M derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2022-03-31 | $67.00K 10-Q · filed 2023-05-04 | $562.00K derived: sum of 2 quarters · filed 2024-03-15 | $562.00K derived: sum of 3 quarters · filed 2024-03-15 | $562.00K derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2021-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $495.00K derived: sum of 2 quarters · filed 2024-03-15 | $495.00K derived: sum of 3 quarters · filed 2024-03-15 | $495.00K 10-K · filed 2024-03-15 | -$495.00K 10-K · filed 2022-03-09 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |